デフォルト表紙
市場調査レポート
商品コード
1053746

腫瘍/癌治療薬の世界市場の成長機会・産業予測 (2021-2030年):薬剤クラスタイプ (化学療法・標的療法・免疫療法・ホルモン療法)・適応症別

Oncology/Cancer Drugs Market By Drug Class Type (Chemotherapy, Targeted Therapy, Immunotherapy, and Hormonal Therapy), By Indication : Opportunity Analysis and Industry Forecast, 2021-2030

出版日: | 発行: Allied Market Research | ページ情報: 英文 252 Pages | 納期: 2~3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=135.61円
腫瘍/癌治療薬の世界市場の成長機会・産業予測 (2021-2030年):薬剤クラスタイプ (化学療法・標的療法・免疫療法・ホルモン療法)・適応症別
出版日: 2021年11月22日
発行: Allied Market Research
ページ情報: 英文 252 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の腫瘍/癌治療薬の市場規模は、2020年の1,354億9,417万米ドルから、2021年から2030年にかけて7.5%のCAGRで推移し、2030年には2,744億63万米ドルの規模に成長すると予測されています。

さまざまなタイプの癌の治療には、モノクローナル抗体(mAb)をベースにした生物学的薬剤が好ましい選択肢として浮上しています。癌の発生率の上昇、先進的な治療法(生物学的治療法や標的薬剤治療法)の普及、世界の高齢者の増加などが同市場の成長を促進する主な要因となっています。また、癌に対する意識の高まり、癌の早期発見、抗癌剤の入手のしやすさなども市場成長を後押しすると考えられています。さらに、新興国の潜在性の高さや、パイプラインの数の多さが参入事業者に新たな機会を示すと期待されています。一方で、新薬の開発にかかる高いコストや、抗癌剤治療に伴う失敗や副作用の恐れが市場成長を抑制すると予測されています。

当レポートでは、世界の腫瘍/癌治療薬の市場を調査し、市場の定義と概要、市場影響因子の分析、臨床試験の動向、市場規模の推移・予測、薬剤クラスタイプ・適応症・地域/主要国など各種区分別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

  • 市場の定義と範囲
  • 主な調査結果
  • 主要企業の位置付け
  • ポーターのファイブフォース分析
  • 臨床試験
  • 市場力学
    • 促進要因
    • 抑制要因
    • 市場機会
    • 影響分析
  • COVID-19:影響分析

第4章 腫瘍/癌治療薬市場:薬剤クラスタイプ別

  • 概要
  • 化学療法
  • 標的療法
  • 免疫療法
  • ホルモン療法
    • 主要市場動向・成長要因・機会
    • 市場規模・予測
    • 市場分析:国別

第5章 腫瘍/癌治療薬市場:適応症別

  • 概要
  • 肺癌
  • 胃癌
  • 大腸癌
  • 乳癌
  • 前立腺癌
  • 肝臓癌
  • 食道癌
  • 子宮頸癌
  • 腎臓癌
  • 膀胱癌
  • その他
    • 市場規模・予測:地域別
    • 市場分析:国別

第6章 腫瘍/癌治療薬市場:地域別

  • 概要
  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ・中東・アフリカ

第7章 企業プロファイル

  • ABBVIE INC.
  • AMGEN, INC.
  • ASTELLAS PHARMA INC.
  • ASTRAZENECA PLC
  • BRISTOL-MYERS SQUIBB COMPANY
  • F. HOFFMANN-LA ROCHE AG
  • JOHNSON & JOHNSON
  • MERCK & CO., INC.
  • NOVARTIS INTERNATIONAL AG
  • PFIZER, INC.
図表

LIST OF TABLES

  • TABLE 01.COMPLETED CLINICAL TRIALS IN CANCER DRUGS MARKET, 2017-2021
  • TABLE 02.GLOBAL ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2020-2030 ($MILLION)
  • TABLE 03.CHEMOTHERAPY ONCOLOGY/CANCER DRUGS MARKET, BY REGION, 2020-2030 ($MILLION)
  • TABLE 04.TARGETED THERAPY ONCOLOGY/CANCER DRUGS MARKET, BY REGION, 2020-2030 ($MILLION)
  • TABLE 05.IMMUNOTHERAPY ONCOLOGY/CANCER DRUGS MARKET, BY REGION, 2020-2030 ($MILLION)
  • TABLE 06.HORMONAL THERAPY ONCOLOGY/CANCER DRUGS MARKET, BY REGION, 2020-2030 ($MILLION)
  • TABLE 07.ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 08.ONCOLOGY/CANCER DRUGS MARKET FOR LUNG CANCER, BY REGION, 2020-2030 ($MILLION)
  • TABLE 09.ONCOLOGY/CANCER DRUGS MARKET FOR STOMACH CANCER, BY REGION, 2020-2030 ($MILLION)
  • TABLE 10.ONCOLOGY/CANCER DRUGS MARKET FOR COLORECTAL CANCER, BY REGION, 2020-2030 ($MILLION)
  • TABLE 11.ONCOLOGY/CANCER DRUGS MARKET FOR BREAST CANCER, BY REGION, 2020-2030 ($MILLION)
  • TABLE 12.ONCOLOGY/CANCER DRUGS MARKET FOR PROSTATE CANCER, BY REGION, 2020-2030 ($MILLION)
  • TABLE 13.ONCOLOGY/CANCER DRUGS MARKET FOR LIVER CANCER, BY REGION, 2020-2030 ($MILLION)
  • TABLE 14.ONCOLOGY/CANCER DRUGS MARKET FOR ESOPHAGEAL CANCER, BY REGION, 2020-2030 ($MILLION)
  • TABLE 15.ONCOLOGY/CANCER DRUGS MARKET FOR CERVICAL CANCER, BY REGION, 2020-2030 ($MILLION)
  • TABLE 16.ONCOLOGY/CANCER DRUGS MARKET FOR KIDNEY CANCER, BY REGION, 2020-2030 ($MILLION)
  • TABLE 17.ONCOLOGY/CANCER DRUGS MARKET FOR BLADDER CANCER, BY REGION, 2020-2030 ($MILLION)
  • TABLE 18.ONCOLOGY/CANCER DRUGS MARKET FOR OTHER CANCER, BY REGION, 2020-2030 ($MILLION)
  • TABLE 19.ONCOLOGY/CANCER DRUGS MARKET, BY REGION, 2020-2030 ($MILLION)
  • TABLE 20.NORTH AMERICA ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 21.U.S. ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2020-2030 ($MILLION)
  • TABLE 22.U.S. ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 23.CANADA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2020-2030 ($MILLION)
  • TABLE 24.CANADA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 25.MEXICO ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2020-2030 ($MILLION)
  • TABLE 26.MEXICO ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 27.NORTH AMERICA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2020-2030 ($MILLION)
  • TABLE 28.NORTH AMERICA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 29.EUROPE ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 30.GERMANY ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2020-2030 ($MILLION)
  • TABLE 31.GERMANY ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 32.FRANCE ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2020-2030 ($MILLION)
  • TABLE 33.FRANCE ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 34.UK ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2020-2030 ($MILLION)
  • TABLE 35.UK ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 36.ITALY ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2020-2030 ($MILLION)
  • TABLE 37.ITALY ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 38.SPAIN ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2020-2030 ($MILLION)
  • TABLE 39.SPAIN ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 40.REST OF EUROPE ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2020-2030 ($MILLION)
  • TABLE 41.REST OF EUROPE ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 42.EUROPE ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2020-2030 ($MILLION)
  • TABLE 43.EUROPE ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 44.ASIA-PACIFIC ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 45.JAPAN ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2020-2030 ($MILLION)
  • TABLE 46.JAPAN ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 47.CHINA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2020-2030 ($MILLION)
  • TABLE 48.CHINA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 49.AUSTRALIA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2020-2030 ($MILLION)
  • TABLE 50.AUSTRALIA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 51.INDIA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2020-2030 ($MILLION)
  • TABLE 52.INDIA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 53.SOUTH KOREA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2020-2030 ($MILLION)
  • TABLE 54.SOUTH KOREA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 55.REST OF ASIA-PACIFIC ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2020-2030 ($MILLION)
  • TABLE 56.REST OF ASIA-PACIFIC ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 57.ASIA-PACIFIC ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2020-2030 ($MILLION)
  • TABLE 58.ASIA-PACIFIC ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 59.LAMEA ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 60.BRAZIL ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2020-2030 ($MILLION)
  • TABLE 61.BRAZIL ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 62.SAUDI ARABIA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2020-2030 ($MILLION)
  • TABLE 63.SAUDI ARABIA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 64.SOUTH AFRICA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2020-2030 ($MILLION)
  • TABLE 65.SOUTH AFRICA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 66.REST OF LAMEA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2020-2030 ($MILLION)
  • TABLE 67.REST OF LAMEA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 68.LAMEA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2020-2030 ($MILLION)
  • TABLE 69.LAMEA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 70.ABBVIE: COMPANY SNAPSHOT
  • TABLE 71.ABBVIE: OPERATING SEGMENTS
  • TABLE 72.ABBVIE: PRODUCT PORTFOLIO
  • TABLE 73.ABBVIE: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 74.AMGEN: COMPANY SNAPSHOT
  • TABLE 75.AMGEN: OPERATING SEGMENTS
  • TABLE 76.AMGEN: PRODUCT PORTFOLIO
  • TABLE 77.AMGEN: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 78.ASTELLAS PHARMA: COMPANY SNAPSHOT
  • TABLE 79.ASTELLAS PHARMA: OERATING SEGMENT
  • TABLE 80.ASTELLAS PHARMA: PRODUCT PORTFOLIO
  • TABLE 81.ASTELLAS PHARMA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 82.ASTRAZENECA: COMPANY SNAPSHOT
  • TABLE 83.ASTRAZENECA: OPERATING SEGMENTS
  • TABLE 84.ASTRAZENECA: PRODUCT PORTFOLIO
  • TABLE 85.ASTRAZENECA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 86.BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT
  • TABLE 87.BRISTOL-MYERS SQUIBB: OPERATING SEGMENTS
  • TABLE 88.BRISTOL-MYERS SQUIBB: PRODUCT PORTFOLIO
  • TABLE 89.ROCHE: COMPANY SNAPSHOT
  • TABLE 90.ROCHE: OPERATING SEGMENTS
  • TABLE 91.ROCHE: PRODUCT PORTFOLIO
  • TABLE 92.ROCHE: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 93.J&J: COMPANY SNAPSHOT
  • TABLE 94.J&J: OPERATING BUSINESS SEGMENTS
  • TABLE 95.J&J: PRODUCT PORTFOLIO
  • TABLE 96.J&J: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 97.MERCK: COMPANY SNAPSHOT
  • TABLE 98.MERCK: OPERATING SEGMENTS
  • TABLE 99.MERCK: PRODUCT PORTFOLIO
  • TABLE 100.MERCK: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 101.NOVARTIS: COMPANY SNAPSHOT
  • TABLE 102.NOVARTIS: OERATING SEGMENT
  • TABLE 103.NOVARTIS: PRODUCT PORTFOLIO
  • TABLE 104.NOVARTIS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 105.PFIZER: COMPANY SNAPSHOT
  • TABLE 106.PFIZER: OPERATING SEGMENT
  • TABLE 107.PFIZER: PRODUCT TYPE PORTFOLIO
  • TABLE 108.PFIZER: KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES

  • FIGURE 01.GLOBAL ONCOLOGY/CANCER DRUGS MARKET SEGMENTATION
  • FIGURE 02.TOP INVESTMENT POCKETS
  • FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2019-2021
  • FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2019-2021
  • FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2019-2021
  • FIGURE 06.TOP PLAYER POSITIONING, 2020
  • FIGURE 07.HIGH BARGAINING POWER OF SUPPLIERS
  • FIGURE 08.HIGH BARGAINING POWER OF BUYERS
  • FIGURE 09.MODERATE THREAT OF SUBSTITUTES
  • FIGURE 10.HIGH THREAT OF NEW ENTRANTS
  • FIGURE 11.HIGH INTENSITY OF RIVALRY
  • FIGURE 12.IMPACT ANALYSIS
  • FIGURE 13.COMPARATIVE ANALYSIS OF CHEMOTHERAPY ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 14.COMPARATIVE ANALYSIS OF TARGETED THERAPY ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 15.COMPARATIVE ANALYSIS OF IMMUNOTHERAPY ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 16.COMPARATIVE ANALYSIS OF HORMONAL THERAPY ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 17.COMPARATIVE ANALYSIS OF LUNG CANCER ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 2020-2030 (%)
  • FIGURE 18.COMPARATIVE ANALYSIS OF STOMACH CANCER ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 2020- 2030 (%)
  • FIGURE 19.COMPARATIVE ANALYSIS OF COLORECTAL CANCER ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 2020-2030 (%)
  • FIGURE 20.COMPARATIVE ANALYSIS OF BREAST CANCER ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 2020-2030 (%)
  • FIGURE 21.COMPARATIVE ANALYSIS OF PROSTATE CANCER ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 2020- 2030 (%)
  • FIGURE 22.COMPARATIVE ANALYSIS OF LIVER CANCER ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 2020- 2030 (%)
  • FIGURE 23.COMPARATIVE ANALYSIS OF ESOPHAGEAL CANCER ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 2020- 2030 (%)
  • FIGURE 24.COMPARATIVE ANALYSIS OF CERVICAL CANCER ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 2020- 2030 (%)
  • FIGURE 25.COMPARATIVE ANALYSIS OF KIDNEY CANCER ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 2020- 2030 (%)
  • FIGURE 26.COMPARATIVE ANALYSIS OF BLADDER CANCER ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 2020- 2030 (%)
  • FIGURE 27.COMPARATIVE ANALYSIS OF OTHER CANCER ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 2020- 2030 (%)
  • FIGURE 28.U.S. ONCOLOGY CANCER DRUGS MARKET, 2020-2030 ($MILLION)
  • FIGURE 29.CANADA ONCOLOGY CANCER DRUGS MARKET, 2020-2030 ($MILLION)
  • FIGURE 30.MEXICO ONCOLOGY CANCER DRUGS MARKET, 2020-2030 ($MILLION)
  • FIGURE 31.GERMANY ONCOLOGY CANCER DRUGS MARKET, 2020-2030 ($MILLION)
  • FIGURE 32.FRANCE ONCOLOGY CANCER DRUGS MARKET, 2020-2030 ($MILLION)
  • FIGURE 33.UK ONCOLOGY CANCER DRUGS MARKET, 2020-2030 ($MILLION)
  • FIGURE 34.ITALY ONCOLOGY CANCER DRUGS MARKET, 2020-2030 ($MILLION)
  • FIGURE 35.SPAIN ONCOLOGY CANCER DRUGS MARKET, 2020-2030 ($MILLION)
  • FIGURE 36.REST OF EUROPE ONCOLOGY CANCER DRUGS MARKET, 2020-2030 ($MILLION)
  • FIGURE 37.JAPAN ONCOLOGY CANCER DRUGS MARKET, 2020-2030 ($MILLION)
  • FIGURE 38.CHINA ONCOLOGY CANCER DRUGS MARKET, 2020-2030 ($MILLION)
  • FIGURE 39.AUSTRALIA ONCOLOGY CANCER DRUGS MARKET, 2020-2030 ($MILLION)
  • FIGURE 40.INDIA ONCOLOGY CANCER DRUGS MARKET, 2020-2030 ($MILLION)
  • FIGURE 41.SOUTH KOREA ONCOLOGY CANCER DRUGS MARKET, 2020-2030 ($MILLION)
  • FIGURE 42.REST OF ASIA-PACIFIC ONCOLOGY/CANCER DRUGS MARKET, 2020-2030 ($MILLION)
  • FIGURE 43.BRAZIL ONCOLOGY/CANCER DRUGS MARKET, 2020-2030 ($MILLION)
  • FIGURE 44.SAUDI ARABIA ONCOLOGY/CANCER DRUGS MARKET, 2020-2030 ($MILLION)
  • FIGURE 45.SOUTH AFRICA ONCOLOGY/CANCER DRUGS MARKET, 2020-2030 ($MILLION)
  • FIGURE 46.REST OF LAMEA ONCOLOGY/CANCER DRUGS MARKET, 2020-2030 ($MILLION)
  • FIGURE 47.ABBVIE: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 48.ABBVIE: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 49.AMGEN: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 50.AMGEN: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 51.ASTELLAS PHARMA: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 52.ASTELLAS PHARMA: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 53.ASTRAZENECA: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 54.ASTRAZENECA: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 55.BRISTOL-MYERS SQUIBB: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 56.BRISTOL-MYERS SQUIBB: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 57.ROCHE: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 58.ROCHE: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 59.ROCHE: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 60.J&J: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 61.J&J: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 62.J&J: REVENUE SHARE BY REGION, 2020(%)
  • FIGURE 63.MERCK: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 64.MERCK: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 65.MERCK: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 66.NOVARTIS: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 67.NOVARTIS: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 68.NOVARTIS: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 69.PFIZER: REVENUE, 2018-2020 ($MILLION)
  • FIGURE 70.PFIZER: REVENUE SHARE BY REGION, 2020 (%)
目次
Product Code: A00042

The global oncology/cancer drugs market was valued at $135,494.17 million in 2020, and is projected to reach $274,400.63 million by 2030, registering a CAGR of 7.5% from 2021 to 2030.

Cancer is the uncontrolled growth of abnormal cells in the body. Cancer develops when the body's normal control mechanism stops working. Old cells do not die and instead grow out of control, forming new, abnormal cells. The treatment of cancer in patients requires the use of different drugs like hormonal therapy, immunotherapy, targeted therapy, and chemotherapy.

Biological drugs based on monoclonal antibodies (mAbs) have emerged as a preferred option to treat various cancer types. Rise in incidence of various cancer conditions, increase in popularity of advance therapies (biological and targeted drug therapies), and surge in geriatric population worldwide are the key factors driving the growth of the global oncology/cancer drugs market. Furthermore, rise in cancer awareness, early screening of the cancer and availability of cancer drugs are expected to boost the market growth.

However, high cost involved in new drug development coupled with threat of failure & adverse effects associated with cancer drugs therapies is expected to restrain the growth of the market. Conversely, high potential of emerging economies and higher number of potential drugs in pipeline are expected to provide new opportunities for market players in future.

The global oncology/cancer drugs market is segmented based on drug class type, indication, and region. Depending on drug class type, the market is divided into chemotherapy, targeted therapy, immunotherapy (biologic therapy), and hormonal therapy. By indication, it is categorized into lung cancer, stomach cancer, colorectal cancer, breast cancer, prostate cancer, liver cancer, esophagus cancer, cervical cancer, kidney cancer, bladder cancer, and other cancers.

Region wise, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA). The major companies profiled in the report include AbbVie Inc., Amgen, Astellas Pharma Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson (Janssen Global Services, LLC,), Merck & Co., Inc., Novartis AG, and Pfizer Inc.

KEY BENEFITS FOR STAKEHOLDERS

  • This report provides a detailed quantitative analysis of the current market trends and future estimations from 2020 to 2030, which assists to identify the prevailing market opportunities.
  • An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate region-specific plans.
  • A comprehensive analysis of the factors that drive and restrain the growth of the oncology/cancer drugs market is provided.
  • An extensive analysis of various regions provides insights that allow companies to strategically plan their business moves.

KEY MARKET SEGMENTS

BY DRUG CLASS TYPE

  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy (Biologic Therapy)
  • Hormonal Therapy

BY INDICATION

  • Lung Cancer
  • Stomach Cancer
  • Colorectal Cancer
  • Breast Cancer
  • Prostate Cancer
  • Liver Cancer
  • Esophagus Cancer
  • Cervical Cancer
  • Kidney Cancer
  • Bladder Cancer
  • Other Cancers

By REGION

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia Pacific
  • Japan
  • China
  • Australia
  • India
  • South Korea
  • Rest of Asia Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

KEY MARKET PLAYERS

  • AbbVie Inc.
  • Amgen
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson (Janssen Global Services, LLC,)
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key benefits for stakeholders
  • 1.3.Key market segments
    • 1.3.1.List of key players profiled in the report
  • 1.4.Research methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
    • 3.2.2.Top winning strategies
  • 3.3.Top player positioning, 2020
  • 3.4.Porter's five force analysis
  • 3.5.Clinical trials
  • 3.6.Market dynamics
    • 3.6.1.Drivers
      • 3.6.1.1.Rise in incidence of cancer across the globe
      • 3.6.1.2.Surge in the global geriatric population
      • 3.6.1.3.Increase in government expenditure on healthcare
    • 3.6.2.Restraint
      • 3.6.2.1.Adverse effect associated with the use cancer drugs
    • 3.6.3.Opportunities
      • 3.6.3.1.High growth potential in untapped emerging economies
      • 3.6.3.2.Increase in number of pipeline drugs
    • 3.6.4.Impact analysis
  • 3.7.COVID-19 Impact Analysis on Oncology/cancer Drugs Market

CHAPTER 4:ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE

  • 4.1.Overview
    • 4.1.1.Market size and forecast
  • 4.2.Chemotherapy
    • 4.2.1.Key market trends, growth factors, and opportunities
    • 4.2.2.Market size and forecast, by region
    • 4.2.3.Market analysis, by country
  • 4.3.Targeted therapy
    • 4.3.1.Key market trends, growth factors, and opportunities
    • 4.3.2.Market size and forecast
    • 4.3.3.Market analysis, by country
  • 4.4.Immunotherapy
    • 4.4.1.Key market trends, growth factors, and opportunities
    • 4.4.2.Market size and forecast
    • 4.4.3.Market analysis, by country
  • 4.5.Hormonal therapy
    • 4.5.1.Key market trends, growth factors, and opportunities
    • 4.5.2.Market size and forecast
    • 4.5.3.Market analysis, by country

CHAPTER 5:ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION

  • 5.1.Overview
    • 5.1.1.Market size and forecast
  • 5.2.Lung Cancer
    • 5.2.1.Market size and forecast, by region
    • 5.2.2.Market analysis, by country
  • 5.3.Stomach Cancer
    • 5.3.1.Market size and forecast, by region
    • 5.3.2.Market analysis, by country
  • 5.4.Colorectal Cancer
    • 5.4.1.Market size and forecast, by region
    • 5.4.2.Market analysis, by country
  • 5.5.Breast Cancer
    • 5.5.1.Market size and forecast, by region
    • 5.5.2.Market analysis, by country
  • 5.6.Prostate Cancer
    • 5.6.1.Market size and forecast, by region
    • 5.6.2.Market analysis, by country
  • 5.7.Liver Cancer
    • 5.7.1.Market size and forecast, by region
    • 5.7.2.Market analysis, by country
  • 5.8.Esophageal cancer
    • 5.8.1.Market size and forecast, by region
    • 5.8.2.Market analysis, by country
  • 5.9.Cervical Cancer
    • 5.9.1.Market size and forecast, by region
    • 5.9.2.Market analysis, by country
  • 5.10.Kidney Cancer
    • 5.10.1.Market size and forecast, by region
    • 5.10.2.Market analysis, by country
  • 5.11.Bladder Cancer
    • 5.11.1.Market size and forecast, by region
    • 5.11.2.Market analysis, by country
  • 5.12.Other Cancers
    • 5.12.1.Market size and forecast, by region
    • 5.12.2.Market analysis, by country

CHAPTER 6:ONCOLOGY/CANCER DRUGS MARKET, BY REGION

  • 6.1.Overview
    • 6.1.1.Market size and forecast
  • 6.2.North America
    • 6.2.1.Key market trends, growth factors, and opportunities
      • 6.2.2.1.U.S.
      • 6.2.2.1.1.U.S. Oncology/cancer drugs market, by drug class type
      • 6.2.2.1.2.U.S. Oncology/cancer drugs market, By indication
      • 6.2.2.2.Canada
      • 6.2.2.2.1.Canada Oncology/cancer drugs market, by drug class type
      • 6.2.2.2.2.Canada Oncology/cancer drugs market, By indication
      • 6.2.2.3.Mexico
      • 6.2.2.3.1.Mexico Oncology/cancer drugs market, by drug class type
      • 6.2.2.3.2.Mexico Oncology/cancer drugs market, By indication
    • 6.2.3.North America market size and forecast, by drug class type
    • 6.2.4.North America market size and forecast, By indication
  • 6.3.Europe
    • 6.3.1.Key market trends, growth factors, and opportunities
    • 6.3.2.Market size and forecast, by country
      • 6.3.2.1.Germany
      • 6.3.2.1.1.Germany Oncology/cancer drugs market, by drug class type
      • 6.3.2.1.2.Germany Oncology/cancer drugs market, By indication
      • 6.3.2.2.France
      • 6.3.2.2.1.France Oncology/cancer drugs market, by drug class type
      • 6.3.2.2.2.France Oncology/cancer drugs market, By indication
      • 6.3.2.3.UK
      • 6.3.2.3.1.UK Oncology/cancer drugs market, by drug class type
      • 6.3.2.3.2.UK Oncology/cancer drugs market, By indication
      • 6.3.2.4.Italy
      • 6.3.2.4.1.Italy Oncology/cancer drugs market, by drug class type
      • 6.3.2.4.2.Italy Oncology/cancer drugs market, By indication
      • 6.3.2.5.Spain
      • 6.3.2.5.1.Spain Oncology/cancer drugs market, by drug class type
      • 6.3.2.5.2.Spain Oncology/cancer drugs market, By indication
      • 6.3.2.6.Rest of Europe
      • 6.3.2.6.1.Rest of Europe Oncology/cancer drugs market, by drug class type
      • 6.3.2.6.2.Rest of Europe Oncology/cancer drugs market, By indication
    • 6.3.3.Europe market size and forecast, by drug class type
    • 6.3.4.Europe market size and forecast, By indication
  • 6.4.Asia-Pacific
    • 6.4.1.Key market trends, growth factors, and opportunities
    • 6.4.2.Market size and forecast, by country
      • 6.4.2.1.Japan
      • 6.4.2.1.1.Japan Oncology/cancer drugs market, by drug class type
      • 6.4.2.1.2.Japan Oncology/cancer drugs market, By indication
      • 6.4.2.2.China
      • 6.4.2.2.1.China Oncology/cancer drugs market, by drug class type
      • 6.4.2.2.2.China Oncology/cancer drugs market, By indication
      • 6.4.2.3.Australia
      • 6.4.2.3.1.Australia Oncology/cancer drugs market, by drug class type
      • 6.4.2.3.2.Australia Oncology/cancer drugs market, By indication
      • 6.4.2.4.India
      • 6.4.2.4.1.India Oncology/cancer drugs market, by drug class type
      • 6.4.2.4.2.India Oncology/cancer drugs market, By indication
      • 6.4.2.5.South Korea
      • 6.4.2.5.1.South Korea Oncology/cancer drugs market, by drug class type
      • 6.4.2.5.2.South Korea Oncology/cancer drugs market, By indication
      • 6.4.2.6.Rest of Asia-Pacific
      • 6.4.2.6.1.Rest of Asia-Pacific Oncology/cancer drugs market, by drug class type
      • 6.4.2.6.2.Rest of Asia-Pacific Oncology/cancer drugs market, By indication
    • 6.4.3.Asia-Pacific market size and forecast, by drug class type
    • 6.4.4.Asia-Pacific market size and forecast, By indication
  • 6.5.LAMEA
    • 6.5.1.Key market trends, growth factors, and opportunities
    • 6.5.2.Market size and forecast, by country
      • 6.5.2.1.Brazil
      • 6.5.2.1.1.Brazil Oncology/cancer drugs market, by drug class type
      • 6.5.2.1.2.Brazil Oncology/cancer drugs market, By indication
      • 6.5.2.2.Saudi Arabia
      • 6.5.2.2.1.Saudi Arabia Oncology/cancer drugs market, by drug class type
      • 6.5.2.2.2.Saudi Arabia Oncology/cancer drugs market, By indication
      • 6.5.2.3.South Africa
      • 6.5.2.3.1.South Africa Oncology/cancer drugs market, by drug class type
      • 6.5.2.3.2.South Africa Oncology/cancer drugs market, By indication
      • 6.5.2.4.Rest of LAMEA
      • 6.5.2.4.1.Rest of LAMEA Oncology/cancer drugs market, by drug class type
      • 6.5.2.4.2.Rest of LAMEA Oncology/cancer drugs market, By indication
    • 6.5.3.LAMEA market size and forecast, by drug class type
    • 6.5.4.LAMEA market size and forecast, By indication

CHAPTER 7:COMPANY PROFILES

  • 7.1.ABBVIE INC.
    • 7.1.1.Company overview
    • 7.1.2.Company snapshot
    • 7.1.3.Operating business segments
    • 7.1.4.Product portfolio
    • 7.1.5.Business performance
    • 7.1.6.Key strategic moves and developments
  • 7.2.AMGEN, INC.
    • 7.2.1.Company overview
    • 7.2.2.Company snapshot
    • 7.2.3.Operating business segments
    • 7.2.4.Product portfolio
    • 7.2.5.Business performance
    • 7.2.6.Key strategic moves and developments
  • 7.3.ASTELLAS PHARMA INC.
    • 7.3.1.Company overview
    • 7.3.2.Company snapshot
    • 7.3.3.Operating business segments
    • 7.3.4.Product portfolio
    • 7.3.5.Business performance
    • 7.3.6.Key strategic moves and developments
  • 7.4.ASTRAZENECA PLC
    • 7.4.1.Company overview
    • 7.4.2.Company snapshot
    • 7.4.3.Operating business segments
    • 7.4.4.Product portfolio
    • 7.4.5.Business performance
    • 7.4.6.Key strategic moves and developments
  • 7.5.BRISTOL-MYERS SQUIBB COMPANY
    • 7.5.1.Company overview
    • 7.5.2.Company snapshot
    • 7.5.3.Operating business segments
    • 7.5.4.Product Portfolio
    • 7.5.5.Business performance
    • 7.5.6.Key strategic moves and developments
  • 7.6.F. HOFFMANN-LA ROCHE AG
    • 7.6.1.Company overview
    • 7.6.2.Company snapshot
    • 7.6.3.Operating business segments
    • 7.6.4.Product portfolio
    • 7.6.5.Business performance
    • 7.6.6.Key strategic moves and developments
  • 7.7.JOHNSON & JOHNSON
    • 7.7.1.Company overview
    • 7.7.2.Company snapshot
    • 7.7.3.Operating business segments
    • 7.7.4.Product portfolio
    • 7.7.5.Business performance
    • 7.7.6.Key strategic moves and developments
  • 7.8.MERCK & CO., INC.
    • 7.8.1.Company overview
    • 7.8.2.Company snapshot
    • 7.8.3.Operating business segments
    • 7.8.4.Product portfolio
    • 7.8.5.Business performance
    • 7.8.6.Key strategic moves and developments
  • 7.9.NOVARTIS INTERNATIONAL AG
    • 7.9.1.Company overview
    • 7.9.2.Company snapshot
    • 7.9.3.Operating business segments
    • 7.9.4.Product portfolio
    • 7.9.5.Business performance
    • 7.9.6.Key strategic moves and developments
  • 7.10.PFIZER, INC.
    • 7.10.1.Company overview
    • 7.10.2.Company snapshot
    • 7.10.3.Operating business segments
    • 7.10.4.Product portfolio
    • 7.10.5.Business performance
    • 7.10.6.Key strategic moves and development